NVAX240628C9500
- 3.17
- -0.94-22.87%
Novavax Newsroom
Where Will Novavax Be in 1 Year?
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
Express News | U.S. Cdc: Updated 2024-2025 Flu Vaccines Will All Be Trivalent and Will Protect Against an H1N1, H3N2 and a B/Victoria Lineage Virus
Express News | U.S. Cdc: Updated Covid-19 Vaccines Will Be Available From Moderna, Novavax, and Pfizer Later This Year
Express News | Novavax- Updated Version of Novavax Covid-19 Vaccine Currently Under Review by U.S. FDA for Eua to Prevent Covid-19 in Individuals Aged 12 and Older
Express News | Novavax - Intends to Provide Doses of 2024-2025 Covid-19 Vaccine at Start of Vaccination Season and Upon Eua by U.S. Food and Drug Administration
Express News | Novavax Inc - U.S. Acip Recommends Use of Authorized and Approved 2024-2025 Covid-19 Vaccines
Express News | U.S. Cdc Advisers Recommend Updated Covid-19 Vaccines for Persons Aged Six Months and Above
Novavax Insiders Sold US$593k Of Shares Suggesting Hesitancy
Novavax, Inc. (NASDAQ:NVAX) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When evaluating insider transactions, knowing whether insiders are
U.S. ACIP Recommends Use of Authorized and Approved 2024-2025 COVID-19 Vaccines
Today the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of a universal recommendation for the use of 2024-2025
Decoding Novavax's Options Activity: What's the Big Picture?
Whales with a lot of money to spend have taken a noticeably bullish stance on Novavax.Looking at options history for Novavax (NASDAQ:NVAX) we detected 10 trades.If we consider the specifics of each tr
Novavax(NVAX.US) Director Sells US$105.68K in Common Stock
$Novavax(NVAX.US)$ Director YOUNG JAMES F sold 7,500 shares of common stock on Jun 21, 2024 at an average price of $14.09 for a total value of $105.68K.Source: Announcement What is statement of change
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 6.35% on an annualized basis producing an average annual return of 19.29%. Currently, Novavax has a market capitalization of
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Novavax Seeks EU Authorization for Updated Covid-19 Vaccine
Novavax (NVAX) said Monday it has submitted an application with the European Medicines Agency for a type 2 variation of its marketing authorization for its JN.1 Covid-19 vaccine for persons at least 1
Express News | Novavax: Filed for a Type II Variation of Existing Marketing Authorization With EMA for Jn.1 Covid-19 Vaccine for Individuals Aged 12 and Older
Express News | Novavax: Intends to Have Vaccine in Unit-Dose Vials Available for Distribution in European Union for Immediate Release Post-Approval
Express News | Novavax Submits Application to European Medicines Agency for Updated Protein-Based 2024-2025 Formula Covid-19 Vaccine
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It